Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1241-1250 Newer>

The Motley Fool June 17, 2004 Seth Jayson	Big Business vs. Big Pharma An organization of human resources executives from companies that employ 12% of the private sector U.S. workforce is working to create a prescription drug "buyer's club," with the help of HR management firm Hewitt Associates.
The Motley Fool June 17, 2004 Brian Gorman	Genentech's Unique Drug Genentech and Biogen Idec's Phase II trial demonstrating Rituxan's effectiveness in treating moderate-to-severe rheumatoid arthritis was enshrined in the prestigious pages of the New England Journal of Medicine, adding heft to the study's results.
The Motley Fool June 17, 2004 Seth Jayson	P&G Patches Up Sex Life? Proctor & Gamble announced that a second phase 3 clinical trial had demonstrated the safety and efficacy of its testosterone patch, to be called Intrinsa, for treating sexual dysfunction in women.
The Motley Fool June 17, 2004 Charly Travers	No Heartburn for Santarus As a small company, Santarus is definitely going to have its hands full marketing the new heartburn drug Rapinex against some of the biotech giants.
National Defense July 2004 Joe Pappalardo	Emergency Rooms Unprepared for Bio-Attacks Of all the safety nets designed to cope with a biological attack in U.S. cities, emergency rooms are among the least prepared, lacking diagnostic tools and trained personnel, experts told a Senate panel.
The Motley Fool June 16, 2004 W.D. Crotty	Nothing Depressing Cyberonics Cyberonics Gets FDA nod; shareholder Boston Scientific gets a portfolio boost.
The Motley Fool June 16, 2004 Alyce Lomax	It's Half-Time at MedImmune The company will slash the price of FluMist.
The Motley Fool June 15, 2004 Brian Gorman	Abbott's Gambit Abbott Laboratories is making a high-stakes stand on drug pricing in a dispute that threatens to make hostages out of the pharmaceutical industry and its investors.
The Motley Fool June 15, 2004 Charly Travers	QLT Swallows Atrix Atrix Laboratories has been purchased by Canadian drug company QLT. For Atrix shareholders, the timing of this deal must be incredibly frustrating.
The Motley Fool June 14, 2004 Brian Gorman	Elan Teams Up With Lilly The companies' manufacturing agreement may be more of a positive sign for Eli Lilly than it is for Elan.
<Older 1241-1250 Newer> Return to current articles.